CompletedInterventional · Phase 1/2NCT02158858 ↗A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
CompletedInterventional · Phase 3NCT03149003 ↗A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)Howard Alan FinePIInterventionDrug: DSP-7888 Dosing Emulsion · Drug: BevacizumabDatesDec 2017 – Aug 2021· Results postedSponsorBoston Biomedical Inc.Glioblastoma
CompletedInterventional · Not applicableNCT03259763 ↗EUS-guided Gastroenterostomy Versus Enteral Stenting for Palliation of Malignant Gastric Outlet Obstruction: A Randomized Clinical TrialReem Z. SharaihaPIInterventionDevice: Lumen-apposing metal stent · Device: Self-expandable metal stentDatesOct 2020 – Jun 2025· Results postedSponsorThe Johns Hopkins UniversityGastric Outlet Obstruction
CompletedInterventional · Phase 1NCT03625505 ↗A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaEllen K. RitchiePIInterventionDrug: Venetoclax · Drug: GilteritinibDatesOct 2018 – Aug 2021SponsorAbbVie Inc.Acute Myeloid Leukemia (AML)
CompletedInterventional · Phase 2NCT03822351 ↗A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)Ashish SaxenaPIInterventionDrug: Durvalumab + Oleclumab · Drug: Durvalumab · Drug: Durvalumab + MonalizumabDatesDec 2018 – Jul 2023· Results postedSponsorMedImmune, LLCStage III Non-small Cell Lung CancerUnresectable
CompletedInterventional · Phase 2NCT03915951 ↗A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerAshish SaxenaPIInterventionDrug: encorafenib · Drug: binimetinibDatesJun 2019 – Sep 2022· Results postedSponsorArray BioPharma Inc.Non-small Cell Lung Cancer
CompletedInterventional · Not applicableNCT04179305 ↗Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2Holly G PrigersonPIInterventionBehavioral: Oncolo-GIST · Behavioral: Usual Care ArmDatesOct 2020 – Jul 2022· Results postedSponsorWeill Medical College of Cornell UniversityCritical IllnessOncologyCommunication
CompletedInterventional · Phase 3NCT04472598 ↗A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)Ellen K. RitchiePIInterventionDrug: Placebo for Navitoclax · Drug: Ruxolitinib · Drug: NavitoclaxDatesSep 2020 – Apr 2023· Results postedSponsorAbbVie Inc.Myelofibrosis (MF)
CompletedInterventional · Phase 1/2NCT04669899 ↗Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor MalignanciesBarbara MaPIInterventionDrug: JTX-8064 · Drug: pimivalimabDatesJan 2021 – Nov 2023SponsorJounce Therapeutics, Inc.Cancer
CompletedObservationalNCT05255445 ↗Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients (RBC-IMPACT)Melissa CushingPIInterventionBiological: Red Blood Cell (RBC) TransfusionDatesMar 2022 – Mar 2024SponsorNational Heart, Lung, & Blood InstituteSickle Cell DiseaseThalassemiaPediatric Cancer
CompletedInterventional · Phase 2NCT05673811 ↗A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerAlana NguyenPIInterventionDrug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01DatesJan 2023 – Mar 2025· Results postedSponsorTheriva Biologics, Inc.Pancreatic AdenocarcinomaMetastatic